MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position

Business Wire11-13

Reaffirms Continuation of Evaluation of Strategic Alternatives SAN DIEGO, November 12, 2024--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the "Company") today reported results for its quarter ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483005080?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-13 05:05","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2483005080","market":"us","top_or_hot":-1,"title":"MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position","media":"Business Wire","content":"<div>\n<p>Reaffirms Continuation of Evaluation of Strategic Alternatives\nSAN DIEGO, November 12, 2024--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the \"Company\") today reported results for its quarter ...</p>\n\n<a href=\"https://finance.yahoo.com/news/mei-pharma-reports-first-quarter-210500371.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-13 05:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/mei-pharma-reports-first-quarter-210500371.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Reaffirms Continuation of Evaluation of Strategic Alternatives\nSAN DIEGO, November 12, 2024--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the \"Company\") today reported results for its quarter ...</p>\n\n<a href=\"https://finance.yahoo.com/news/mei-pharma-reports-first-quarter-210500371.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MEI","symbol_name":"Methode Electronics Inc","start_time":0,"source_url":"https://finance.yahoo.com/news/mei-pharma-reports-first-quarter-210500371.html","article_id":"2483005080","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483005080","pubTimestamp":1731445500,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"SAN DIEGO, November 12, 2024----MEI Pharma, Inc.   today reported results for its quarter ended September 30, 2024.As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. In the review, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders. Oppenheimer & Co., Inc. is serving as the Company’s exclusive financial advisor in this process.During the first quarter of fiscal year 2025, the Company commenced cash preservation efforts that include a reduction-in-force, which will continue in stages as the Company’s operational and strategic direction evolves.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MEI":"Methode Electronics Inc","MEIP":"MEI Pharma","BK4145":"电子制造服务","BK4139":"生物科技"},"translate_title":"MEI Pharma报告2025财年第一季度现金状况","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MEI":1,"MEIP":1},"content_text":"Reaffirms Continuation of Evaluation of Strategic Alternatives\nSAN DIEGO, November 12, 2024--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the \"Company\") today reported results for its quarter ended September 30, 2024.\nAs previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. In the review, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders. Oppenheimer & Co., Inc. is serving as the Company’s exclusive financial advisor in this process.\nDuring the first quarter of fiscal year 2025, the Company commenced cash preservation efforts that include a reduction-in-force, which will continue in stages as the Company’s operational and strategic direction evolves.\nThere can be no assurance the exploration of strategic alternatives will result in any agreements or transactions, or, if completed, any agreements or transactions will be successful or on attractive terms. The Company does not expect to disclose developments with respect to this process unless or until the evaluation of strategic alternatives has been completed or the Board of Directors has concluded disclosure is appropriate or legally required.\nAs of September 30, 2024, MEI had $26.9 million in cash, cash equivalents, and short-term investments with no outstanding debt.\nAbout MEI Pharma\nMEI Pharma, Inc. (Nasdaq: MEIP) is a clinical-stage pharmaceutical company with a portfolio of several drug candidates that may offer novel and differentiated cancer therapies. The drug candidate pipeline includes voruciclib, an oral cyclin-dependent kinase 9 inhibitor. For more information, please visit www.meipharma.com. Follow us on X (formerly Twitter) @MEI_Pharma and on LinkedIn.\nForward-Looking Statements\nCertain information contained in this press release that are not historical in nature are \"forward-looking statements\" within the meaning of the \"safe harbor\" provisions of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements regarding the Company’s ability to identify, assess and execute a strategic transaction or realize value from its existing assets, the Company’s ability to preserve cash in order to adequately fund an orderly wind down of its operations if no transaction is consummated, the ability of stockholders and other stakeholders to realize any value or recovery as part of a transaction or a wind down process, the Company’s workforce reduction and future charges expected to be incurred in connection therewith, the adequacy or sufficiency of the Company’s existing cash resources and other statements. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management’s current expectations and are subject to a number of risks and uncertainties, including, but not limited to the Company’s ability to identify attractive strategic alternatives; the Company’s ability to retain key personnel; the adequacy of the Company’s capital resources in light of changing circumstances; the actions of various stakeholders of the Company; uncertainty regarding the impact of rising inflation and the increase in interest rates as a result; potential economic downturn; activist investors; government regulation; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.\n\n\n\nMEI PHARMA, INC.\n\n\nCONDENSED CONSOLIDATED BALANCE SHEETS\n\n\n(In thousands, except par value amounts)\n\n\n\n\n\n\nSeptember 30,\n\nJune 30,\n\n\n\n2024\n\n2024\n\n\n\n(Unaudited)\n\n(Audited)\n\n\nASSETS\n\n\nCurrent assets:\n\n\n\n\n\n\n\nCash and cash equivalents\n$\n6,952\n\n\n$\n3,705\n\n\n\nShort-term investments\n\n19,953\n\n\n\n34,640\n\n\n\nPrepaid expenses and other current assets\n\n840\n\n\n\n2,424\n\n\n\nTotal current assets\n\n27,745\n\n\n\n40,769\n\n\n\nOperating lease right-of-use asset\n\n—\n\n\n\n214\n\n\n\nProperty and equipment, net\n\n5\n\n\n\n392\n\n\n\nTotal assets\n$\n27,750\n\n\n$\n41,375\n\n\n\n\n\n\n\n\n\n\n\nLIABILITIES AND STOCKHOLDERS' EQUITY\n\n\nCurrent liabilities:\n\n\n\n\n\n\n\nAccounts payable\n$\n976\n\n\n$\n3,168\n\n\n\nAccrued liabilities\n\n1,896\n\n\n\n5,187\n\n\n\nTotal current liabilities\n\n2,872\n\n\n\n8,355\n\n\n\nTotal liabilities\n\n2,872\n\n\n\n8,355\n\n\n\n\n\n\n\n\n\n\n\nStockholders' equity:\n\n\n\n\n\n\n\nPreferred stock, $0.01 par value; 100 shares authorized;\n\n\n\n\n\n\n\nnone outstanding\n\n—\n\n\n\n—\n\n\n\nCommon stock, $0.00000002 par value; 226,000 shares\n\n\n\n\n\n\n\nauthorized; 6,663 shares issued and outstanding\n\n\n\n\n\n\n\nat September 30, 2024 and June 30, 2024, respectively\n\n—\n\n\n\n—\n\n\n\nAdditional paid-in-capital\n\n421,104\n\n\n\n421,239\n\n\n\nAccumulated deficit\n\n(396,226\n)\n\n\n(388,219\n)\n\n\nTotal stockholders' equity\n\n24,878\n\n\n\n33,020\n\n\n\nTotal liabilities and stockholders' equity\n$\n27,750\n\n\n$\n41,375\n\n\n\n\n\n\n\nMEI PHARMA, INC.\n\n\nCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS\n\n\n(In thousands, except per share amounts)\n\n\n\n\n\n\nFor the Three Months Ended September 30,\n\n\n\n2024\n\n2023\n\n\n\n(Unaudited)\n\n\n\n\n\n\n\n\n\n\nRevenues\n$\n—\n\n\n$\n65,297\n\n\n\nOperating expenses:\n\n\n\n\n\n\n\nResearch and development\n\n3,163\n\n\n\n3,485\n\n\n\nGeneral and administrative\n\n5,189\n\n\n\n6,531\n\n\n\nTotal operating expenses\n\n8,352\n\n\n\n10,016\n\n\n\n(Loss) income from operations\n\n(8,352\n)\n\n\n55,281\n\n\n\nOther income (expense):\n\n\n\n\n\n\n\nInterest and dividend income\n\n355\n\n\n\n1,094\n\n\n\nOther expense, net\n\n(10\n)\n\n\n(1\n)\n\n\nNet (loss) income\n$\n(8,007\n)\n\n$\n56,374\n\n\n\n\n\n\n\n\n\n\n\nNet (loss) income per share - basic and diluted\n$\n(1.20\n)\n\n$\n8.46\n\n\n\n\n\n\n\n\n\n\n\nWeighted-average shares used in computing net(loss) income per share - basic and diluted\n\n6,663\n\n\n\n6,663\n\n\n\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20241112133837/en/\nContacts\nJustin J. File858-898-0976investor@meipharma.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483005080"}